Stoke Therapeutics, Inc. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7eb3333e-ae72-4230-873d-a3eb81e3758f/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $184.4M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-108362 |
| FY 2024 | $36.6M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-041170 |
| FY 2023 | $8.8M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-035912 |
| FY 2022 | $12.4M | 2022-01-01 – 2022-12-31 | evidence 0001564590-23-003175 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Stoke Therapeutics, Inc. — all facts · Net Income · Operating Income